<DOC>
	<DOCNO>NCT00440726</DOCNO>
	<brief_summary>This Phase I/II study drug call bortezomib give combination chemotherapy drug use treat acute lymphoblastic leukemia ( ALL ) come back ( recur ) . Bortezomib drug approve Food Drug Administration ( FDA ) treat adult multiple myeloma type blood cancer . Bortezomib show cause cancer cell die study do animal ( mouse ) . Studies do show adult child cancer show response bortezomib use alone . Studies also do adult evaluate dose bortezomib safely give combination chemotherapy drug . The Phase I portion study complete dose phase II portion study 1.3mg/m2/day . The phase II portion study open accruing .</brief_summary>
	<brief_title>Bortezomib With Chemotherapy Relapsed Pediatric Acute Lymphoblastic Leukemia ( ALL )</brief_title>
	<detailed_description>All patient receive 1 course chemotherapy unless medical complication prevent administration drug . Treatment last 1 month . Treatment study consist combination 7 anti-cancer medication . The 7 anti-cancer medicine bortezomib , vincristine , dexamethasone , PEG-asparaginase , doxorubicin , cytarabine ( Ara-C ) , methotrexate ( MTX ) . If Phase I portion study , give assign dose bortezomib . The dose bortezomib base dos give previous study do adult child . At dose level bortezomib , 3 6 child receive bortezomib combination chemotherapy . If side effect severe , next group child receive high dose . The dose continue increase find dose cause serious side effect . Your dose bortezomib increase . If bad side effect , dose may decrease . The dose use Phase 2 part study determine outcome Phase I study . The high dose use Phase I tolerate without serious side effect one use Phase 2 .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Pegaspargase</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>This abbreviated list . Patients must great 1 year less 21 year age participate study . Patients must relapse acute lymphoblastic leukemia ( ALL ) without evidence central nervous system ( CNS ) disease . Patients must adequate kidney , heart , liver function . Patients pregnant breast feed . Patients allergy asparaginase product Patients active uncontrolled infection . Patients numbness tingle hand foot constipation .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Acute Lymphoblastic Leukemia</keyword>
	<keyword>Pediatrics</keyword>
	<keyword>Relapsed</keyword>
	<keyword>Recurrence</keyword>
	<keyword>Bortezomib</keyword>
	<keyword>Velcade</keyword>
	<keyword>Therapeutic Advances Childhood Leukemia</keyword>
	<keyword>Investigational</keyword>
	<keyword>Childhood</keyword>
	<keyword>ALL</keyword>
	<keyword>Relapsed ALL</keyword>
	<keyword>Refractory ALL</keyword>
	<keyword>Relapsed pediatric ALL</keyword>
	<keyword>Refractory pediatric ALL</keyword>
	<keyword>TACL</keyword>
	<keyword>Recurrent Pediatric ALL</keyword>
</DOC>